NEW YORK (GenomeWeb News) – NewBridge Pharmaceuticals today announced an agreement to offer Verinata Health's non-invasive prenatal tests in the Middle East and surrounding areas.

Under the exclusive agreement, NewBridge will offer Verinata's Verifi test in the Middle East, Africa, Turkey, and Caspian regions. Financial terms of the deal were not disclosed.

Based in Dubai, United Arab Emirates, NewBridge is a specialty therapeutics firm that commercializes pharmaceuticals, biologics, diagnostics, and medical devices in the Middle East and neighboring areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.